Compare AbCellera Biologics Inc (ABCL) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs VanEck Vietnam ETF — how do they compare? AbCellera Biologics Inc trades at $10.3 (market cap $2.99B), while VanEck Vietnam ETF trades at $17.8. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VNM | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $19.80 |
52-Week Low | $2.78 | $16.34 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
VNM stock trades at $17.80, up 0.91% with a bullish technical signal despite mixed indicators. The stock faces resistance at $18 with support at $17. Recent news highlights Vietnam's economic challenges including power grid strain and FTSE Russell's EM reclassification affecting foreign investment flows.
The stock shows technical strength but faces fundamental data gaps and regional economic headwinds. Investment opportunity exists if Vietnam's market reclassification attracts foreign capital, though power infrastructure risks and broader Asian equity outflows present near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
